Optimus Holding Ltd.’s Acquisition Of OM Pharma


Bär & Karrer acts as legal advisor to Vifor Pharma in this transaction. PwC Deals supported Vifor and OM Pharma with Financial and Carve-out related Vendor Assistance.

Vifor Pharma, a global leader in iron deficiency, nephrology and cardio-renal therapies, has sold its OM Pharma business, which primarily focuses on therapies for respiratory and urinary tract infections and is active in the treatment of vascular diseases, to Optimus Holding Ltd., a company founded by Etienne Jornod together with long-standing Swiss entrepreneurs and the Turkish pharmaceutical company Abdi Ibrahim.

The acquisition of 100% of the share capital amounts to MCHF 435 and includes an earn out related to potential future value gains on 20% of Optimus Holding Ltd. Equity, which could increase the total transaction value in excess of MCHF 500, to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple. Completion is expected to take place in the following days.

Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries and exporting to 60 countries worldwide, as a strategic partner. Optimus Holding is fully committed to the sustainable growth of OM Pharma and to invest considerably in R&D to become a global biotechnology company focused on improving the lives of patients with respiratory and inflammatory diseases.

Bär & Karrer advised Vifor Pharma in this transaction with a team included Christoph Neeracher (Picture), Raphael Annasohn and Lukas Bründler (all M&A), Susanne Schreiber and Elena Kumashova (both Tax), Markus Wang (IP) as well as Mani Reinert (Antitrust).

PwC Deals advised Vifor and OM Pharma on the deal with a team included Nico Psarras, Luca Borrelli, Rense Balk, Gregory Mustillo and Quoc Fu Ha.

Involved fees earner: Raphael Annasohn – Bär & Karrer; Lukas Bründler – Bär & Karrer; Elena Kumashova – Bär & Karrer; Christoph Neeracher – Bär & Karrer; Mani Reinert – Bär & Karrer; Susanne Schreiber – Bär & Karrer; Markus Wang – Bär & Karrer; Rense Balk – PwC Switzerland; Luca Borrelli – PwC Switzerland; Quoc Fu Ha – PwC Switzerland; Gregory Mustillo – PwC Switzerland; Nico Psarras – PwC Switzerland;

Law Firms: Bär & Karrer; PwC Switzerland;

Clients: Vifor Pharma;